- Conditions
- Hepatic Impairment (HI)
- Interventions
- EDG-7500
- Drug
- Lead sponsor
- Edgewise Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 2
- States / cities
- Miami, Florida • Orlando, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–8
of 8
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Hepatic Insufficiency
- Interventions
- Mavorixafor
- Drug
- Lead sponsor
- X4 Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 4
- States / cities
- Montclair, California • Rialto, California • Orlando, Florida + 1 more
- Conditions
- Primary Biliary Cholangitis, Compensated Cirrhosis, Hepatic Impairment
- Interventions
- Seladelpar
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 11
- States / cities
- Chandler, Arizona • Sacramento, California • Aurora, Colorado + 7 more
- Conditions
- Hepatic Impairment (HI)
- Interventions
- Nemtabrutinib
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 3
- States / cities
- Miami, Florida • Orlando, Florida • San Antonio, Texas
- Conditions
- Hepatic Impairment, Moderate Hepatic Impairment
- Interventions
- Zanzalintinib
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- Orlando, Florida • San Antonio, Texas
- Conditions
- Healthy Volunteer, Hepatic Impairment (HI)
- Interventions
- varegacestat
- Drug
- Lead sponsor
- Immunome, Inc.
- Industry
- Eligibility
- 18 Years to 84 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- Orlando, Florida • San Antonio, Texas
- Conditions
- Hepatic Impairment
- Interventions
- BPN14770
- Drug
- Lead sponsor
- Shionogi
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 3
- States / cities
- Miami, Florida • Orlando, Florida • San Antonio, Texas
- Conditions
- Hepatic Impairment, Healthy Volunteers
- Interventions
- Mobocertinib
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 2
- States / cities
- Hialeah, Florida • Orlando, Florida